IMiD Sequencing in Relapsed Multiple Myeloma with Paul G. Richardson, MD Case 1
IMiD Sequencing in Relapsed Multiple Myeloma with Paul G. Richardson, MD
Case Scenario 1:
July 2011
- The patient is a 61-year-old Caucasian female who was diagnosed with stage II MM. Genetic testing showed her to have t(4:16). At the time she was treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy followed by autologous stem cell transplantation.
- She achieved a partial response with RVD and remained in remission. Based on her high-risk cytogenetics, the patient was placed on lenalidomide maintenance therapy.
August 2016
- Routine follow up shows that her M-protein levels have now risen to 1.4 g/dL and her light chain levels continue to rise.
- Although she has developed mild anemia and her creatinine level is slightly elevated to 1.3 mg/dL, she continues to work full-time, has no bone pain, and a has a normal calcium level.
Recent Videos
Related Content
MRD Negativity Improves With D-VRd in Newly Diagnosed, Transplant-Eligible Myeloma
September 6th 2024Article
Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.
Read More
Lower-Intensity Talquetamab Dose Shows Potential in Multiple Myeloma
August 30th 2024Article
During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
